Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Conditions
Interventions
Pegilodecakin
Paclitaxel or Docetaxel and Carboplatin or Cisplatin
+8 more
Locations
10
United States
UCLA Medical Hematology & Oncology
Los Angeles, California, United States
UCSF
San Francisco, California, United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
November 15, 2013
Primary Completion Date
February 19, 2019
Completion Date
July 22, 2023
Last Updated
November 15, 2024
NCT06844383
NCT07177937
NCT06926283
NCT02621021
NCT06594926
NCT06487507
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions